From KRAS G12C breakthroughs to emerging KRAS G12D and NRAS strategies, the MAPK pathway is reshaping the treatment landscape across solid tumors — with market potential set to grow from $4B to $13B by 2031.

In this factsheet, Lumanity’s oncology experts outline:

    • Key market trends driving innovation and competitive shifts

    • Strategic imperatives for established players, emerging innovators, and opportunistic entrants

    • Watchpoints to track evolving standards of care, resistance patterns, and combination opportunities

Whether you’re refining your clinical development strategy or scouting whitespace for new opportunities, this resource distills the market intelligence you need to make smarter, faster decisions.

Download resource

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Sign me up to receive regular insights from Lumanity
By selecting this box, I consent to receive Lumanity marketing communications by email.